Literature DB >> 12969517

Expression of LRRC4 has the potential to decrease the growth rate and tumorigenesis of glioblastoma cell line U251.

Jie-Ru Wang1, Xiao-Ling Li, Song-Qing Fan, Chen Tan, Juan-Juan Xiang, Ke Tang, Rong Wang, Gui-Yuan Li.   

Abstract

BACKGROUND &
OBJECTIVE: LRRC4 is a novel gene that the author has identified recently, which displayed significant downregulation in primary brain tumor biopsies. This study was designed to investigate if LRRC4 has the potential of suppressing brain tumor growth.
METHODS: The full-length coding region of LRRC4 gene was subcloned into the expression vector pcDNA3.1, the recombinant was introduced into the glioblastoma cell line U251 by liposome transfection, and the U251 cells stably expressing LRRC4 gene were established by G418 selection. Furthermore, cell proliferation assay, soft agar assay, tumorigenesis assay were taken to examine the effect of LRRC4 expression on cell growth and tumor formation.
RESULTS: U251 cells stably expressing full-length coding region of LRRC4 were established by lipofection-mediated transfection and selected for further study. Compared with the nontransfected and vector-transfected cells, the cells transfected with LRRC4 cDNA exhibited a significant increase of expression of LRRC4 mRNA by Northern blot analysis. Further, when cell proliferation was followed over several days, the cells expressing the transfected LRRC4 cDNA grew more slowly than nontransfected cells. Consistently, the cells transfected with LRRC4 exhibited markedly lower colony formation rate. These clones were injected into athymic nude mice who was killed after 40 days and the tumor sizes were evaluated. Tumor volume in mice was significantly smaller in the group of cells stably transfected with LRRC4 cDNA than in the control.
CONCLUSION: LRRC4 gene may be transfected into the human glioblastoma cell line U251. The expression of LRRC4 in U251 cells may have the potential to suppress tumor cell growth and the tumorigenesis of U251 cell transplanted in nude mice.

Entities:  

Mesh:

Year:  2003        PMID: 12969517

Source DB:  PubMed          Journal:  Ai Zheng


  5 in total

1.  Genome-wide association study across pediatric central nervous system tumors implicates shared predisposition and points to 1q25.2 (PAPPA2) and 11p12 (LRRC4C) as novel candidate susceptibility loci.

Authors:  Jon Foss-Skiftesvik; Christian Munch Hagen; René Mathiasen; Dea Adamsen; Marie Bækvad-Hansen; Anders D Børglum; Merete Nordentoft; Thomas Werge; Michael Christiansen; Kjeld Schmiegelow; Marianne Juhler; Preben Bo Mortensen; David Michael Hougaard; Jonas Bybjerg-Grauholm
Journal:  Childs Nerv Syst       Date:  2020-11-23       Impact factor: 1.475

2.  Structural analysis of cDNAs coding for 4SNc-Tudor domain protein from fish and their expression in yellowtail organs.

Authors:  Shunnosuke Abe; Pi-Lin Wang; Fuminori Takahashi; Eiji Sasaki
Journal:  Mar Biotechnol (NY)       Date:  2005-08-23       Impact factor: 3.619

3.  Identification of Protein Tyrosine Phosphatase Receptor Type O (PTPRO) as a Synaptic Adhesion Molecule that Promotes Synapse Formation.

Authors:  Wei Jiang; Mengping Wei; Mengna Liu; Yunlong Pan; Dong Cao; Xiaofei Yang; Chen Zhang
Journal:  J Neurosci       Date:  2017-09-04       Impact factor: 6.167

4.  Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide.

Authors:  Bee Hui Liu; Chacko Jobichen; C S Brian Chia; Tim Hon Man Chan; Jing Ping Tang; Theodora X Y Chung; Jia Li; Anders Poulsen; Alvin W Hung; Xiaoying Koh-Stenta; Yaw Sing Tan; Chandra S Verma; Hong Kee Tan; Chan-Shuo Wu; Feng Li; Jeffrey Hill; Joma Joy; Henry Yang; Li Chai; J Sivaraman; Daniel G Tenen
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-05       Impact factor: 11.205

5.  Disturbing miR-182 and -381 inhibits BRD7 transcription and glioma growth by directly targeting LRRC4.

Authors:  Hailin Tang; Zeyou Wang; Qing Liu; Xiaoping Liu; Minghua Wu; Guiyuan Li
Journal:  PLoS One       Date:  2014-01-03       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.